Answers are grounded in this paper and cite their sources.
Fungal co-infections are increasingly reported in hospitalized COVID-19 patients; but their clinical significance remains uncertain. We conducted a retrospective cohort study of 3373 hospitalized patients with COVID-19 to evaluate the association between fungal isolates and in-hospital mortality. Fungal isolates were identified in 197 (5.8%) patients, predominantly from respiratory specimens, with non-albicans Candida species accounting for most isolates. Patients with fungal isolates were older, had longer hospital stays, and exhibited higher rates of comorbidities, intensive care use, and exposure to broad-spectrum antibiotics, corticosteroids, and tocilizumab. In-hospital mortality was higher among patients with fungal isolates (18.8% vs. 12.2%, p=0.009). However, in multivariable logistic regression analysis, fungal isolates were not independently associated with mortality (adjusted OR 1.49, 95% CI 0.97-2.29). Mortality was independently associated with age, chronic kidney disease, immunosuppression, and treatment-related factors. These findings suggest that fungal isolates are more likely markers of disease severity and treatment exposure rather than direct contributors to mortality.
No takes yet. Share an insight, caveat, or question.
Aliu-Bejta et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: